Market closed
Emergent BioSolutions/$EBS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
900
ISIN
US29089Q1058
Website
EBS Metrics
BasicAdvanced
$307M
-
-$2.46
-
-
Price and volume
Market cap
$307M
52-week high
$15.10
52-week low
$4.02
Average daily volume
1.3M
Financial strength
Current ratio
6.316
Quick ratio
3.153
Long term debt to equity
120.445
Total debt to equity
120.445
Interest coverage (TTM)
-0.69%
Management effectiveness
Return on assets (TTM)
-1.63%
Return on equity (TTM)
-21.63%
Valuation
Price to revenue (TTM)
0.313
Price to book
0.56
Price to tangible book (TTM)
4.56
Price to free cash flow (TTM)
1.96
Growth
Revenue change (TTM)
-18.56%
Earnings per share change (TTM)
-77.52%
3-year revenue growth (CAGR)
-18.10%
3-year earnings per share growth (CAGR)
-6.09%
What the Analysts think about EBS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
EBS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EBS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EBS News
AllArticlesVideos
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Seeking Alpha·5 days ago
Emergent BioSolutions Reports First Quarter 2025 Financial Results
GlobeNewsWire·5 days ago
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $307M as of May 13, 2025.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of May 13, 2025.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of May 13, 2025.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) does not currently have a Beta indicator.